


Causal Inference Case Studies

Irene Y. Chen

 @irenetrampoline



6.S897 / HST.956 Machine Learning for Healthcare: Recitation 6



Housekeeping

1. Midsemester feedback form

- We read every comment
- Already taking suggestions into account

2. Final project mentors

- Received initial feedback
- Email TAs with questions

3. HW5 out


- Mystery poll??

Agenda for today


- ~~1. Housekeeping~~
2. Review lecture material [15 mins]
3. Post surgical opioid abuse [15 mins]
4. Diabetes treatment management [15 mins]

Goal: learn practical causality analysis tools for homework, final projects, and beyond

You inherit a tobacco company in the 1950's




smoking



lung cancer

Does smoking cause cancer?




Observed association; cannot do randomized control trial

Does cancer cause smoking?



Probably not: Smoking begins years before diagnosis.

Does smoking cause cancer?




How can we estimate $ATE = E[Y=1 | T=1, X] - E[Y=0 | T=0, X]$?

Three ML methods to control for confounders

1. Covariate adjustment
2. Matching
3. Propensity scoring

Explicitly model the relationship between treatment, confounders, and outcome:



[Slide 4 of lecture 15]

Covariate adjustment (reminder)

- Under ignorability,
 $CATE(x) =$
 $\mathbb{E}_{x \sim p(x)} [\mathbb{E}[Y_1 | T = 1, x] - \mathbb{E}[Y_0 | T = 0, x]]$
- Fit a model $f(x, t) \approx \mathbb{E}[Y_t | T = t, x]$, then:
 $\widehat{CATE}(x_i) = f(x_i, 1) - f(x_i, 0).$

Recap: Covariate adjustment

- “Plug in different values of treatment and see what happens”
- Assumes we have a very accurate and calibrated $f(x, T)$
- If data is nonlinear and we assume linearity, CATE and ATE estimates can be very misleading
- Recent research has investigated using different model classes for f , e.g. random forests and neural networks. We must then figure out how to modify the learning criteria

Matching

- Find each unit's long-lost counterfactual identical twin, check up on his outcome



Obama, had he gone to law school



Obama, had he gone to business school

1-NN Matching

- Let $d(\cdot, \cdot)$ be a metric between x 's
- For each i , define $j(i) = \underset{j \text{ s.t. } t_j \neq t_i}{\operatorname{argmin}} d(x_j, x_i)$

$j(i)$ is the nearest counterfactual neighbor of i

- $t_i = 1$, unit i is treated:

$$\widehat{CATE}(x_i) = y_i - y_{j(i)}$$

- $t_i = 0$, unit i is control:


$$\widehat{CATE}(x_i) = y_{j(i)} - y_i$$

[Slide 18 of lecture 15]

Recap: Matching

- “Approximate my **long lost twin** and compare results”
- Useful for both **CATE and ATE**
- In practice, difficult because of finding **right distance function** and **having enough twins**
- Not used widely (yet!)

What if the populations are different?



Propensity score reweighting

$$ATE = \frac{1}{n_1} \sum_{i \text{ s.t. } t_i=1} \frac{y_i}{\hat{p}(t_i = 1|x_i)} - \frac{1}{n_0} \sum_{i \text{ s.t. } t_i=0} \frac{y_i}{\hat{p}(t_i = 0|x_i)}$$


where n_τ are the effective counts of the re-weighted cohorts:

$$n_\tau = \sum_{i \text{ s.t. } t_i=\tau} \frac{1}{\hat{p}(t_i = \tau | x_i)}$$

Recap: Propensity score reweighting

- “Give higher weight to lower represented samples”
- Can only calculate ATE
- Requires some overlap of the populations and good estimator \hat{p}
- If denominator is too low, weights can explode quickly

What about instrumental variables?



We can then estimate Wald estimator $\text{Cov}(Y, B) / \text{Cov}(T, B)$


Agenda for today

- ~~1. Housekeeping~~
- ~~2. Review lecture material [15 mins]~~
3. Post surgical opioid abuse [15 mins]
4. Diabetes treatment management [15 mins]

Drug overdose deaths in America




*Some deaths on this chart may overlap if they involve multiple drugs.



■ All drugs ■ Opioid painkillers (natural and semisynthetic) ■ Heroin
■ Fentanyl and other synthetic opioids (minus methadone)

[Centers for Disease Control]

Share of organ donors who died of drug overdoses



Source: Organ Procurement and Transplantation Network

Vox

Research

Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study

BMJ 2018 ; 360 doi: <https://doi.org/10.1136/bmj.j5790> (Published 17 January 2018)

Cite this as: *BMJ* 2018;360:j5790

[Article](#)

[Related content](#)

[Metrics](#)

[Responses](#)

[Peer review](#)


Gabriel A Brat, instructor in surgery^{1 2}, Denis Agniel, postdoctoral fellow¹, Andrew Beam, research scientist¹, Brian Yorkgitis, assistant professor in surgery³, Mark Bicket, assistant professor in anesthesia⁴, Mark Homer, postdoctoral fellow¹, Kathe P Fox, director⁵, Daniel B Knecht, chief of staff⁵, Cheryl N McMahon-Walraven, director⁵, Nathan Palmer, research scientist¹, Isaac Kohane, department chair¹

[Author affiliations](#) ▼

Correspondence to: G A Brat gbrat@bidmc.harvard.edu

Accepted 1 December 2017

Do postsurgical opioids cause opioid abuse?



Aetna Insurance claims

Pros

- Complete patient record
- Hospital and pharmacy care
- Surgical claims from CPT, outcomes from ICD-9 codes

Cons

- Lacking granular information about hospital stays (e.g. lab values)
- CPT and ICD-9 codes can be incorrect or manipulated for billing purposes

Data source


Include

- Patients with “complete” medical and pharmacy insurance records
- Underwent first surgery
- Opioid naïve: little/no previous opioid use

Final cohort

- Large dataset (37 million)
- Longitudinal (2008-2016)
- After inclusion criteria, 1 million opioid naïve patients undergoing surgery

Do postsurgical opioids cause opioid abuse?



How do we define T, Y, and X?

What is treatment T?

- Refill
- Total dosage
- Duration of use

What is outcome Y?

- ICD-9 code for opioid dependence, abuse, and overdose
- Only include diagnosis codes related to prescription opioids

What are confounders X?

- Demographics (age, sex)
- US state of residence
- surgery type group
- surgery year
- presurgical diagnoses

Statistical analysis

- Weighted linear regression for log transformed weekly rates of misuse
 - Each week weighted according to sample size
 - Create outcome of adjusted analysis of **time until misuse event** using Cox proportional hazards (survival analysis!)
 - Results report **multiplicative percentage increases** in rate
- Sensitivity analysis to rule out structural confounders
 - Interaction term between duration and year indicator
 - Interaction between duration and state of residence indicator
 - Build in an unobserved confounder with a Bernoulli random variable

Recap: Postsurgical opioid use to misuse


- “Duration more than dosage use may cause opioid misuse”
- Use covariate adjustment to estimate multiplicative effects
- Interaction terms

Agenda for today

- ~~1. Housekeeping~~
- ~~2. Review lecture material [15 mins]~~
- ~~3. Post surgical opioid abuse [15 mins]~~
4. Diabetes treatment management [15 mins]

Personalized Diabetes Management Using Electronic Medical Records

Dimitris Bertsimas¹, Nathan Kallus, Alexander M. Weinstein **and** Ying Daisy Zhuo

 Author Affiliations

Corresponding author: Dimitris Bertsimas, dbertsim@mit.edu.

Diabetes Care 2017 Feb; 40(2): 210-217.

<https://doi.org/10.2337/dc16-0826>



 [Previous](#)

[Next](#) 

Article

Figures & Tables

Suppl Material

Info & Metrics


 PDF

Abstract

OBJECTIVE Current clinical guidelines for managing type 2 diabetes do not differentiate based on patient-specific factors. We present a data-driven algorithm for personalized diabetes management that improves health outcomes relative to the standard of care.

Type 2 Diabetes Treatment Still a Mystery

Figure 2.2 Prevalence (%) of people with diabetes by age and sex, 2013



[BMJ Open](#). 2015; 5(5): e007375.

Published online 2015 May 12. doi: [10.1136/bmjopen-2014-007375](https://doi.org/10.1136/bmjopen-2014-007375)

PMCID: PMC4431069

PMID: [25967997](https://pubmed.ncbi.nlm.nih.gov/25967997/)

Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health Survey

[Sunali D Goonesekera](#), [May H Yang](#), [Susan A Hall](#), [Shona C Fang](#), [Rebecca S Piccolo](#), and [John B McKinlay](#)

► [Author information](#) ► [Article notes](#) ► [Copyright and License information](#) [Disclaimer](#)

[Diabetologia](#). Author manuscript; available in PMC 2014 Dec 1.

Published in final edited form as:

[Diabetologia](#). 2013 Dec; 56(12): 10.1007/s00125-013-3078-7.

Published online 2013 Oct 5. doi: [10.1007/s00125-013-3078-7](https://doi.org/10.1007/s00125-013-3078-7)

PMCID: PMC3842214

NIHMSID: NIHMS529351

PMID: [24092493](https://pubmed.ncbi.nlm.nih.gov/24092493/)

Age-related differences in glycaemic control in diabetes

[Elizabeth Selvin](#)¹ and [Christina M. Parrinello](#)¹

What do we include in this analysis?

Inclusion criteria

- Patients in hospital EMR for >1 year
- Prescription for at least one blood glucose regulation agent
- At least three recorded laboratory results for HbA1C
- No recorded diagnosis of type 1 diabetes (from ICD-9 code 250.x1 or 250.x3)


Final cohort

- 10k patients, 48k patient visits
- Access to demographic information
- Analyze all associated EMR data

What makes two patients similar or different?


Features

- Differentiate 13 lines of therapy
- Patient visit every 100 day and average HbA1C after visit (75-200 days after)
- Collect what standard of care was actually administered




[Slide 17 of lecture 15]

Which treatment will lead to lower HbA1C?



Model


- For each patient visit, find kNN regression to predict HbA1C under every possible treatment
- Algorithm prescribes regimen with best predicted outcome if predictive improvement exceeds threshold
- Evaluation compared actual treatment and outcome with recommended therapy and outcome
- Sensitivity analysis by drawing new training and testing splits



[Figure 1 of Bertsimas et al, 2017]

A

Recommendation: Switch from insulin monotherapy to metformin monotherapy

B Outcomes for similar patients who were prescribed...


Predicted HbA1c (%): 8.3

C

PATIENT ID	12XXXXXX
AGE (Years)	61.9
SEX	F
RACE/ETHNICITY	Black
CURRENT HbA1c (%)	10.1
CURRENT REGIMEN	Insulin

D

Patient Treatment & HbA1c History



[Figure 2 of Bertsimas et al, 2017]

Recap: Diabetes treatment management

- “kNN over patients can recommend diabetes treatments”
- Use matching to estimate different treatment effects
- Evaluate by comparing predicted and actual treatment and HbA1C values
- Sensitivity analysis through repeated sampling of training and test data

Have a great weekend!